Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma

Abstract

Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase/ganciclovir ( HSV-tk /GCV) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy. The aim of this study was to determine whether combining HSV-tk /GCV gene therapy with temozolomide (TMZ), an alkylating drug clinically proven to be efficient in recurrent high-grade gliomas, would result in enhanced antitumor effect in malignant glioma in culture and in vivo. Human U87MG glioblastoma (GBM) cells with or without expression of HSV-tk were treated with different concentrations of GCV, TMZ, or both drugs. Cell viability was accessed by an automated microplate assay (MTT). The isobologram method and the combination index (CI) method of Chou-Talalay were used to measure the interactions between the two drugs when applied simultaneously. U87- tk and control U87 cells (5×106 each) were implanted in the flanks of nude mice, and animals were treated with GCV or TMZ or with both drugs. All tumors were measured and weighed at specified time points. IC50 for GCV was 511 μM in control U87 cells and 14.3 μM in U87- tk cells, resulting in 35.7-fold increase of toxicity in the HSV-tk –expressing cells. TMZ had an IC50 of 20.2 mM in control cells and 2.35 mM in U87- tk cells, resulting in 8.6-fold increase in sensitivity of the HSV-tk –expressing cells. TMZ and HSV-tk /GCV actions were synergistic (CI<1) in both control and U87- tk cells with higher synergism in U87- tk cells at high effect levels. Tumors expressing HSV-tk and treated with TMZ and GCV were significantly smaller than those treated by TMZ, but not by GCV. There was also a significant difference between the weight of HSV-tk expressing versus control tumors treated with TMZ, with GCV, or with both drugs. These data demonstrate synergism between HSV-tk /GCV and TMZ and higher sensitivity against TMZ in HSV-tk –expressing GBM cells. The potential importance for clinical studies combining both local tumor gene therapy and systemic chemotherapy should be explored further. Cancer Gene Therapy (2001) 8, 662–668.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Shugg D, Allen BJ, Blizzard L, et al . Brain cancer incidence, mortality and case survival: Observations from two Australian cancer registries Int J Cancer 1994 59: 765–770

    Article  CAS  PubMed  Google Scholar 

  2. Burger PC, Green SB . Patient age, histologic features and length of survival in patients with glioblastoma multiforme Cancer 1987 59: 1617–1625

    Article  CAS  PubMed  Google Scholar 

  3. Fine HA . The basis fort current treatment recommendations for malignant gliomas J Neurooncol 1994 20: 111–120

    Article  CAS  PubMed  Google Scholar 

  4. Kleihues P, Burger PC, Scheithauer BW . Histological Typing of Tumors of the Central Nervous System 2nd ed Berlin: Springer 1993

    Book  Google Scholar 

  5. Prados MD, Levin V . Biology and treatment of malignant glioma Semin Oncol 2000 27: 1–10

    CAS  PubMed  Google Scholar 

  6. Culver KW, Ram Z, Wallbridge S, et al . In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 1992 256: 1550–1552

    Article  CAS  PubMed  Google Scholar 

  7. Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy Cancer Res 1986 46: 5276–5281

    CAS  PubMed  Google Scholar 

  8. Oldfield EH, Ram Z, Culver KW, et al . Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir Hum Gene Ther 1993 4: 39–69

    Article  CAS  PubMed  Google Scholar 

  9. Ram Z, Culver KW, Oshiro EM, et al . Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nat Med 1997 3: 1354–1361

    Article  CAS  PubMed  Google Scholar 

  10. Shand N, Weber F, Mariani L, et al . A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir Hum Gene Ther 1999 10: 2325–2335

    Article  CAS  PubMed  Google Scholar 

  11. Freeman SM, Abboud CN, Whartenby KA, et al . The “bystander effect”: tumour regression when a fraction of the tumour mass is genetically modified Cancer Res 1993 53: 5274–5283

    CAS  PubMed  Google Scholar 

  12. Rainov NG . A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy for previously untreated glioblastoma multiforme in adults Hum Gene Ther 2000 11: 2389–2401

    Article  CAS  PubMed  Google Scholar 

  13. Baer JC, Freeman AA, Newlands ES, et al . Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells Br J Cancer 1993 67: 1299–1302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bower M, Newlands ES, Bleehen NM, et al . Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma Cancer Chemother Pharmacol 1997 40: 484–488

    Article  CAS  PubMed  Google Scholar 

  15. Avgeropoulos NG, Batchelor TT . New treatment strategies for malignant gliomas Oncologist 1999 4: 209–224

    CAS  PubMed  Google Scholar 

  16. Friedman HS, McLendon RE, Kerby T, et al . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma J Clin Oncol 1998 16: 3851–3857

    Article  CAS  PubMed  Google Scholar 

  17. Newlands ES, O'Reilly SM, Glaser MG, et al . The Charing Cross Hospital experience with temozolomide in patients with gliomas Eur J Cancer 1996 32A: 2236–2241

    Article  CAS  PubMed  Google Scholar 

  18. Yang LY, Li L, Keating MJ, et al . Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin–DNA cross-link repair Mol Pharmacol 1995 47: 1072–1079

    CAS  PubMed  Google Scholar 

  19. Ezzeddine ZD, Martuza RL, Platika D, et al . Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene New Biol 1991 13: 608–614

    Google Scholar 

  20. Chou TC, Talalay P . Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors Eur J Biochem 1981 115: 207–216

    Article  CAS  PubMed  Google Scholar 

  21. Chou TC, Talalay P . Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984 22: 27–55

    Article  CAS  PubMed  Google Scholar 

  22. Chou TC . The median-effect principle and the combination index for quantitation of synergism and antagonism In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy New York: Academic Press 1991 61–102

  23. Chou TC . Drug combinations: from laboratory to practice J Lab Clin Med 1998 132: 6–8

    Article  CAS  PubMed  Google Scholar 

  24. Chou TC, Motzer RJ, Tong Y, et al . Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 1994 86: 1517–1524

    Article  CAS  PubMed  Google Scholar 

  25. Chou TC, Hayball M . CalcuSyn for Windows, multiple drug dose–effect analyzer and manual Biosoft, Cambridge Place, Cambridge, UK 1996

    Google Scholar 

  26. Chen MS, Walker J, Prusoff WH . Kinetic studies of herpes simplex virus type 1-encoded thymidine and thymidylate kinase, a multifunctional enzyme J Biol Chem 1979 254: 10747–10753

    CAS  PubMed  Google Scholar 

  27. Aghi M, Kramm CM, Chou TC, et al . Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies J Natl Cancer Inst 1998 90: 370–380

    Article  CAS  PubMed  Google Scholar 

  28. Faulds D, Heel RC . Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections Drugs 1990 39: 597

    Article  CAS  PubMed  Google Scholar 

  29. Arrowsmith J, Missailidis S, Stevens MF, et al . Antitumour imidazotetrazines: Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing the minor groove Anticancer Drug Des 1999 14: 205–217

    CAS  PubMed  Google Scholar 

  30. Alvino E, Pepponi R, Pagani E, et al . O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity J Pharmacol Exp Ther 1999 291: 1292–1300

    CAS  PubMed  Google Scholar 

  31. Belanich M, Randall T, Pastor MA, et al . Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine–DNA methyltransferase Cancer Chemother Pharmacol 1996 37: 547–555

    Article  CAS  PubMed  Google Scholar 

  32. Aghi M, Chou TC, Suling K, et al . Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies Cancer Res 1999 59: 3861–3865

    CAS  PubMed  Google Scholar 

  33. Ilsley DD, Lee S, Miller WH, et al . Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action Biochemistry 1995 34: 2504–2510

    Article  CAS  PubMed  Google Scholar 

  34. Hammond LA, Eckardt JR, Baker SD, et al . Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies J Clin Oncol 1999 17: 2604–2613

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Grants 2794A/0087H and 3067A/0029G from the Federal State of Saxony-Anhalt (NGR), BioRegio Grant 0311661/1402 from the Federal Ministry of Education and Research of Germany (N.G.R., C.M.K.), a grant from the E.-Kröner-Fresenius foundation (N.G.R.), and a grant from the Bartling Foundation Hannover (N.G.R.).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nikolai G Rainov.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rainov, N., Fels, C., Dröege, J. et al. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther 8, 662–668 (2001). https://doi.org/10.1038/sj.cgt.7700355

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700355

Keywords

This article is cited by

Search

Quick links